Skip to main content

Treatment Clinical Trials for Prostate Cancer

Review the prostate cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 313

Adding the Drug Carboplatin to Cabazitaxel Chemotherapy for People with Castrate-Resistant Prostate Cancer That Has Spread to Other Parts of the Body, CARAVAN Trial
Status: Active
Location: 468 locations
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients with High Risk Prostate Cancer
Status: Active
Location: 371 locations
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy after Surgery for Prostate Cancer, INNOVATE Trial
Status: Active
Location: 329 locations
Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic Therapy with Either Surgery or Radiation Therapy, for Patients with Advanced Prostate Cancer
Status: Active
Location: 322 locations
Docetaxel and Hormone Treatment Compared to Hormone Treatment Alone in People with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response, TRIPLE-SWITCH Trial
Status: Active
Location: 289 locations
Treating Prostate Cancer That Has Come Back after Surgery with Apalutamide and Targeted Radiation Based on PET Imaging, INDICATE Trial
Status: Active
Location: 298 locations
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Status: Active
Location: 475 locations
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
Status: Active
Location: 219 locations
Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Status: Active
Location: 165 locations
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Status: Active
Location: 90 locations
Targeted Treatment for Metastatic Prostate Cancer, PREDICT Trial
Status: Active
Location: 82 locations
Docetaxel with or without Radium Ra 223 Dichloride in Treating Patients with Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: 32 locations
A Study of Two Different Radiotherapy Treatment Strategies Given with Hormone Therapy for Participants with Unfavorable-Risk, Localized Prostate Cancer, ASCENDE-SBRT Trial
Status: Active
Location: 43 locations
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Status: Active
Location: 26 locations
Surgical Removal of Prostate Tumor and Antiandrogen Therapy with or without Docetaxel in Treating Men with Newly Diagnosed Metastatic Prostate Cancer
Status: Active
Location: 18 locations
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Status: Active
Location: 27 locations
Radiation Medication (Radium-223 dichloride) versus Radium-223 dichloride plus Radiation Enhancing Medication (M3814) versus Radium-223 dichloride plus M3814 plus Avelumab (a type of immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Status: Active
Location: 20 locations
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Status: Active
Location: 20 locations
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Status: Active
Location: 15 locations
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Status: Active
Location: 17 locations
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Status: Active
Location: 15 locations
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Status: Active
Location: 16 locations
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Status: Active
Location: 13 locations
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer that has Neuroendocrine Cells
Status: Active
Location: 12 locations
SpaceIT Hydrogel System for Perirectal Spacing
Status: Active
Location: 12 locations